• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

DexTech Medical

10.30 SEK

-1.90 %

Less than 1K followers

DEX

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.90 %
+2.49 %
-4.63 %
+12.57 %
+9.57 %
+38.26 %
+104.37 %
-71.41 %
+5.94 %

DexTech Medical operates in biotechnology. The company conducts research and development in the field of urological oncology, where common diseases include prostate cancer. A large part of the research is carried out in collaboration with other international players, research institutes and universities. The largest operations are found in the Nordic market. The company was founded in 2004 and is headquartered in Uppsala.

Read more
Market cap
190.4M SEK
Turnover
89.01K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
31/8
2026

Annual report '26

Press release6/4/2026, 1:44 PM

Analyst Group: Analyst Group kommenterar DexTechs positiva preliminära resultat i myelomstudien

DexTech Medical
Regulatory press release6/4/2026, 6:00 AM

DexTech Medicals myelomstudie färdigrekryterad, preliminära resultat mycket positiva

DexTech Medical
Regulatory press release6/4/2026, 6:00 AM

DexTech Medical's myeloma study fully recruited, preliminary results very positive

DexTech Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/8/2026, 9:57 AM

Analyst Group: Aktieanalys på DexTech Medical - Från klinisk exekvering till kommersiell realisering

DexTech Medical
Press release5/5/2026, 1:20 PM

Analyst Group: Analyst Group kommenterar DexTechs Q3-rapport för år 2025/26

DexTech Medical
Regulatory press release5/5/2026, 9:30 AM

DexTech Medical AB, Interim Report 1 July 2025 - 31 March 2026

DexTech Medical
Regulatory press release5/5/2026, 9:30 AM

DexTech Medical AB, Delårsrapport 1 juli 2025 - 31 mars 2026

DexTech Medical
Press release3/2/2026, 10:37 AM

Analyst Group: Aktieanalys på DexTech Medical - Genomgående positiv initial behandlingsrespons i fas I–IIa-studien

DexTech Medical
Press release2/25/2026, 2:13 PM

Analyst Group: Analyst Group kommenterar DexTechs Q2-rapport för år 2025/26

DexTech Medical
Regulatory press release2/25/2026, 11:00 AM

DexTech Medical AB Halvårsrapport 1 juli - 31 december 2025

DexTech Medical
Press release1/27/2026, 11:23 AM

Analyst Group: Analyst Group kommenterar att samtliga patienter svarat positivt på OsteoDex i DexTech Medicals fas I-IIa-studie avseende multipelt myelom

DexTech Medical
Regulatory press release1/27/2026, 7:55 AM

DexTech Medicals myelomstudie, färdig i slutet av februari 2026, avslutar med fortsatt starka resultat

DexTech Medical
Regulatory press release1/27/2026, 7:55 AM

DexTech Medical's myeloma study, completed at the end of February 2026, concludes with continued strong results

DexTech Medical
Press release12/3/2025, 1:41 PM

Analyst Group: Analyst Group kommenterar på att samtliga patienter svarat positivt på OsteoDex i DexTech Medicals fas I-studie avseende multipelt myelom

DexTech Medical
Regulatory press release12/3/2025, 8:15 AM

DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3

DexTech Medical
Regulatory press release12/3/2025, 8:15 AM

DexTech Medicals myelomstudie (ODX-MM-001), dosgrupp 2 och dosgrupp 3

DexTech Medical
Press release11/5/2025, 9:57 AM

Analyst Group: Aktieanalys på DexTech Medical - Kliniska framsteg i fas I-studien och finansiell uthållighet

DexTech Medical
Regulatory press release11/4/2025, 1:15 PM

DexTech Medical AB, Bulletin from the Annual General Meeting

DexTech Medical
Regulatory press release11/4/2025, 1:15 PM

DexTech Medical AB, Kommuniké från årsstämma

DexTech Medical
Press release11/3/2025, 1:21 PM

Analyst Group: Analyst Group kommenterar DexTechs Q1-rapport för år 2025/26

DexTech Medical